nach oben

Medical Microbiology and Immunology

Erschienen in:

01.06.2008 | Review

CD8 T-cell-based immunotherapy of cytomegalovirus infection: “proof of concept” provided by the murine model

verfasst von: Rafaela Holtappels, Verena Böhm, Jürgen Podlech, Matthias J. Reddehase

Erschienen in: Medical Microbiology and Immunology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Adoptive transfer of antiviral effector or memory CD8 T cells is a therapeutic option for preventing acute cytomegalovirus (CMV) disease after primary or recurrent infection in immunocompromised recipients of hematopoietic stem cell transplantation (HSCT) aimed at curing hematopoietic malignancies. Preclinical research in murine models has demonstrated the power of CD8 T-cell-based preemptive immunotherapy and has encouraged clinical trials that gave promising results. The clinical evidence, however, is based primarily on statistical analyses indicating a reduced incidence of CMV-associated complications. Here, we will briefly review the data obtained from the murine model showing that CD8 T cells derived from CMV-immune donors and administered either as peptide-selected cytolytic T lymphocyte lines or after ex vivo purification by T-cell-receptor-specific cell sorting can indeed prevent CMV-mediated histopathology and multiple organ failure.

Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411:385–389PubMedCrossRef

Hebart H, Einsele H (2004) Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 65:432–436PubMedCrossRef

Riddell SR (1995) Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts. Semin Respir Infect 10:199–208PubMed

Wills MR, Carmichael AJ, Patrick Sissons JG (2006) Adaptive cellular immunity to human cytomegalovirus. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, pp 341–365

Riddell SR, Greenberg PD (1995) Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 13:545–586PubMedCrossRef

Moss P, Rickinson A (2005) Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol 5:9–20PubMedCrossRef

Pepperl-Klindworth S, Plachter B (2006) Current perspectives in vaccine development. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, pp 551–572

Reddehase MJ, Weiland F, Münch K, Jonjic S, Lüske A, Koszinowski UH (1985) Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 55:264–273PubMedPubMedCentralCrossRef

Reddehase MJ, Mutter W, Koszinowski UH (1987) In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med 165:650–656PubMedCrossRef

10.

Reddehase MJ, Mutter W, Münch K, Bühring HJ, Koszinowski UH (1987) CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102–3108PubMedPubMedCentralCrossRef

11.

Reddehase MJ, Jonjic S, Weiland F, Mutter W, Koszinowski UH (1988) Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors. J Virol 62:1061–1065PubMedPubMedCentralCrossRef

12.

Greenberg PD, Reusser P, Goodrich JM, Riddell SR (1991) Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro. Ann NY Acad Sci 636:184–195PubMedCrossRef

13.

Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238–241PubMedCrossRef

14.

Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1996) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038–1044CrossRef

15.

Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, Mackinnon S (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362:1275–1277CrossRef

16.

Einsele H, Hamprecht K (2003) Immunotherapy of cytomegalovirus infection after stem-cell transplantation: a new option? Lancet 362:1343–1344PubMedCrossRef

17.

Pahl-Seibert M-F, Jülch M, Podlech J, Thomas D, Deegen P, Reddehase MJ, Holtappels R (2005) Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol 79:5400–5413PubMedPubMedCentralCrossRef

18.

Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald C, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, Craddock C, Moss PA (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202:379–386PubMedPubMedCentralCrossRef

19.

Sacher T, Podlech J, Mohr AC, Jordan S, Ruzsics Z, Reddehase MJ, Koszinowski UH (2008) Cell type specific labelling of a herpesvirus: the major virus producing cell type does not contribute to virus dissemination. Cell Host Microbe (in press)

20.

Holtappels R, Munks WM, Podlech J, Reddehase MJ (2006) CD8 T-cell-based immunotherapy of cytomegalovirus disease in the mouse model of the immunocompromised bone marrow transplantation recipient. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, pp 383–418

21.

Reddehase MJ, Simon CO, Seckert CK, Lemmermann N, Grzimek NK (2008) Murine model of cytomegalovirus latency and reactivation. In: Shenk TE, Stinski MF (eds) Human Cytomegalovirus. Current Topics in Microbiology and Immunology 325. Springer, Berlin , pp 315–332

22.

Reddehase MJ (2002) Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2:831–844PubMedCrossRef

23.

Reddehase MJ, Koszinowski UH (1984) Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 312:369–371PubMedCrossRef

24.

Reddehase MJ, Bühring HJ, Koszinowski UH (1986) Cloned long-term cytolytic T-lymphocyte line with specificity for an immediate-early membrane antigen of murine cytomegalovirus. J Virol 57:408–412PubMedPubMedCentralCrossRef

25.

Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, Sissons JG (1988) Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 168:919–931PubMedCrossRef

26.

Kern F, Surel IP, Faulhaber N, Frömmel C, Schneider-Mergener J, Schönemann C, Reinke P, Volk HD (1999) Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton immediate-early protein revisited. J Virol 73:8179–8184PubMedPubMedCentralCrossRef

27.

Gibson L, Piccini G, Lilleri D, Revello MG, Wang Z, Markel S, Diamond DJ, Luzuriaga K (2004) Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 172:2256–2264PubMedCrossRef

28.

Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, Kern F (2005) Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201:1031–1036PubMedPubMedCentralCrossRef

29.

Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ (2005) Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202:673–685PubMedPubMedCentralCrossRef

30.

Starr SE, Allison AC (1977) Role of T lymphocytes in recovery from cytomegalovirus infection. Infect Immun 17:458–462PubMedPubMedCentralCrossRef

31.

Ho M (1980) Role of specific cytotoxic T lymphocytes in cellular immunity against murine cytomegalovirus. Infect Immun 27:767–776PubMedPubMedCentralCrossRef

32.

Holtappels R, Podlech J, Geginat G, Steffens HP, Thomas D, Reddehase MJ (1998) Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates. J Virol 72:7201–7212PubMedPubMedCentralCrossRef

33.

Podlech J, Holtappels R, Wirtz N, Steffens HP, Reddehase MJ (1998) Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation. J Gen Virol 79:2099–2104PubMedCrossRef

34.

Podlech J, Holtappels R, Pahl-Seibert M-F, Steffens HP, Reddehase MJ (2000) Murine model of interstitial cytomegalovirus pneumonia in syngeneic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection. J Virol 74:7496–7507PubMedPubMedCentralCrossRef

35.

Alterio de Goss M, Holtappels R, Steffens HP, Podlech J, Angele P, Dreher L, Thomas D, Reddehase MJ (1998) Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells. J Virol 72:7733–7744CrossRef

36.

Steffens HP, Kurz S, Holtappels R, Reddehase MJ (1998) Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol 72:1797–1804PubMedPubMedCentralCrossRef

37.

Holtappels R, Pahl-Seibert M-F, Thomas D, Reddehase MJ (2000) Enrichment of immediate-early 1(m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J Virol 74:11495–11503PubMedPubMedCentralCrossRef

38.

Simon CO, Holtappels R, Tervo HM, Böhm V, Däubner T, Oehrlein-Karpi SA, Kühnapfel B, Renzaho A, Strand D, Podlech J, Reddehase MJ, Grzimek NK (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80:10436–10456PubMedPubMedCentralCrossRef

39.

Morello CS, Ye M, Spector DH (2002) Development of a vaccine against murine cytomegalovirus (MCMV), consisting of a plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication. J Virol 76:4822–4835PubMedPubMedCentralCrossRef

40.

Holtappels R, Thomas D, Podlech J, Geginat G, Steffens HP, Reddehase MJ (2000) The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells. J Virol 74:1871–1884PubMedPubMedCentralCrossRef

41.

Morello CS, Cranmer LD, Spector DH (2000) Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J Virol 74:3696–3708PubMedPubMedCentralCrossRef

42.

Holtappels R, Podlech J, Grzimek NK, Thomas D, Pahl-Seibert M-F, Reddehase MJ (2001) Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and ppM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65). J Virol 75:6584–6600PubMedPubMedCentralCrossRef

43.

Ye M, Morello CS, Spector DH (2002) Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge. J Virol 76:2100–2112PubMedPubMedCentralCrossRef

44.

Ye M, Morello CS, Spector DH (2004) Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization. J Virol 78:11233–11245PubMedPubMedCentralCrossRef

45.

Morello CS, Kelley LA, Munks MW, Hill AB, Spector DH (2007) DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge. J Virol 81:7766–7775PubMedPubMedCentralCrossRef

46.

Gonzales Armas JC, Morello CS, Cranmer LD, Spector DH (1996) DNA immunization confers protection against murine cytomegalovirus infection. J Virol 70:7921–7928CrossRef

47.

Holtappels R, Thomas D, Podlech J, Reddehase MJ (2002) Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype. J Virol 76:151–164PubMedPubMedCentralCrossRef

48.

Holtappels R, Janda J, Thomas D, Schenk S, Reddehase MJ, Geginat G (2008) Adoptive CD8 T cell control of pathogens cannot be improved by combining protective epitope specificities. J Infect Dis 197:622–629PubMedCrossRef

49.

Hanson LK, Campbell AE (2006) Determinants of macrophage tropism. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, pp 341–365

50.

Mocarski Jr ES, Hahn G, Lofgren White K, Xu J, Slobedman B, Hertel L, Aguirre SA, Noda S (2006) Myeloid cell recruitment and function in pathogenesis and latency. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Norfolk, pp 465–481

51.

Ménard C, Wagner M, Ruzsics Z, Holak K, Brune W, Campbell AE, Koszinowski UH (2003) Role of murine cytomegalovirus US22 gene family members in replication in macrophages. J Virol 77:5557–5570PubMedPubMedCentralCrossRef

52.

Cicin-Sain L, Podlech J, Messerle M, Reddehase MJ, Koszinowski UH (2005) Frequent coinfection of cells explains functional in vivo complementation between cytomegalovirus variants in the multiply infected host. J Virol 79:9492–9502PubMedPubMedCentralCrossRef

53.

Cicin-Sain L, Ruzsics Z, Podlech J, Bubic I, Ménard C, Jonjic S, Reddehase MJ, Koszinowski UH (2008) Dominant-negative FADD rescues the in vivo fitness of a cytomegalovirus lacking an anti-apoptotic viral gene. J Virol 82:2056–2064PubMedCrossRef

54.

Erlach KC, Böhm V, Seckert CK, Reddehase MJ, Podlech J (2006) Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection. J Virol 80:4801–4819PubMedPubMedCentralCrossRef

55.

Jonjic S, Pavic I, Lucin P, Rukavina D, Koszinowski UH (1990) Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol 64:5457–5464PubMedPubMedCentralCrossRef

56.

Polic B, Jonjic S, Pavic I, Crnkovic I, Zorica I, Hengel H, Lucin P, Koszinowski UH (1996) Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo. J Gen Virol 77:217–225PubMedCrossRef

57.

Humphreys IR, Loewendorf A, de Trez C, Schneider K, Benedict CA, Munks MW, Ware CF, Croft M (2007) OX40 costimulation promotes persistence of cytomegalovirus-specific CD8 T cells: a CD4-dependent mechanism. J Immunol 179:2195–2202PubMedCrossRef

58.

Munks MW, Gold MC, Zajac AL, Doom CM, Morello CS, Spector DH, Hill AB (2006) Genome-wide analysis reveals a highly diverse CD8 T cell response to murine cytomegalovirus. J Immunol 176:3760–3766PubMedCrossRef

59.

Gold MC, Munks MW, Wagner M, Koszinowski UH, Hill AB, Fling SP (2002) The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo. J Immunol 169:359–365PubMedCrossRef

60.

Munks MW, Pinto AK, Doom CM, Hill AB (2007) Viral interference with antigen presentation does not alter acute or chronic CD8 T cell immunodominance in murine cytomegalovirus infection. J Immunol 178:7235–7241PubMedCrossRef

61.

Holtappels R, Podlech J, Pahl-Seibert M-F, Jülch M, Thomas D, Simon CO, Wagner M, Reddehase MJ (2004) Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J Exp Med 199:131–136PubMedPubMedCentralCrossRef

62.

Holtappels R, Gillert-Marien D, Thomas D, Podlech J, Deegen P, Herter S, Oehrlein-Karpi SA, Strand D, Wagner M, Reddehase MJ (2006) Cytomegalovirus encodes a positive regulator of antigen presentation. J Virol 80:7613–7624PubMedPubMedCentralCrossRef

63.

Pinto AK, Munks MW, Koszinowski UH, Hill AB (2006) Coordinated function of murine cytomegalovirus genes completely inhibits CTL lysis. J Immunol 177:3225–3234PubMedCrossRef

64.

Hengel H, Jonjic S, Ruppert T, Koszinowski UH (1994) Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J Virol 68:289–297PubMedPubMedCentralCrossRef

Titel: CD8 T-cell-based immunotherapy of cytomegalovirus infection: “proof of concept” provided by the murine model
verfasst von: Rafaela Holtappels
Verena Böhm
Jürgen Podlech
Matthias J. Reddehase
Publikationsdatum: 01.06.2008
Verlag: Springer Berlin Heidelberg
Erschienen in: Medical Microbiology and Immunology / Ausgabe 2/2008
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-008-0093-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

The salivary glands as a privileged site of cytomegalovirus immune evasion and persistence

Epitope-specific in vivo protection against cytomegalovirus disease by CD8 T cells in the murine model of preemptive immunotherapy

Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency

Recombinant viruses as tools to study human cytomegalovirus immune modulation

Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection